News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

News

Webcast

Webcasts

July 18, 2024

IDN Trends, Insights and Strategies Every Manufacturer Should Know

Author(s):

Eversana

Webinar Date/Time: Thu, Aug 8, 2024 1:00 PM EDT

Join this webinar to explore the latest trends and strategies in Integrated Delivery Networks (IDNs). Industry experts will share insights to help manufacturers navigate the IDN landscape, optimize partnerships, and drive growth. Don't miss this opportunity for valuable knowledge and actionable insights!

Register Free: https://www.pharmexec.com/pe/idn-trends

Event Overview:

The healthcare industry is evolving rapidly, and Integrated Delivery Networks (IDNs) are at the forefront of these changes. This exclusive webinar is designed to arm manufacturers with emerging trends, insights and strategies essential for thriving in the evolving IDN landscape. During the webinar, a panel of industry experts will delve into how IDNs operate and what motivates them, offering guidance on navigating this complex terrain, optimizing partnerships and capitalizing on emerging opportunities to drive growth and enhance patient outcomes.


Attendees will walk away with an understanding of IDN market dynamics, operational nuances and best practices supporting collaboration. This webinar promises to deliver invaluable knowledge and actionable insights, empowering participants to master the complexities of the IDN market, forge robust partnerships, and propel their business growth to new heights.


Key Learning Objectives
Join this webinar and learn more about:

  • Understanding IDN Structures: Learn about the organizational structures and key decision-makers within IDNs.
  • Market Dynamics: Explore the current trends shaping the IDN market, including consolidation and the shift towards value-based care.
  • Strategic Partnerships: Discover strategies for building and maintaining effective partnerships with IDNs.
  • Regulatory and Compliance Considerations: Gain insights into the regulatory landscape affecting IDNs and manufacturers.
  • Technology and Innovation: Learn how technology and innovation are transforming IDN operations and how manufacturers can stay ahead of the curve.
  • Best Practices for Engagement: Understand the best practices for engaging with IDNs, including effective communication and value proposition development.

Who Should Attend
C-Suite, Vice President and Director positions within the following:

  • Medical Engagement
  • Medical Communications
  • Scientific Communications
  • Field Medical
  • Commercial
  • Brand
  • Medical Affairs
  • National Accounts
  • Market Access
  • Field Market Access
  • Patient Access
  • Managed Markets
  • Payer Marketing
  • HEOR
  • Health Economics
  • Value & Evidence
  • Value & Access
  • Real-World Evidence

Speakers:

Faruk Abdullah
President, Professional Services and Chief Business Officer
EVERSANA

Faruk leads EVERSANA’s Professional Services division, which includes multiple advisory teams and the Value & Evidence Service line. He is responsible for driving growth and accelerating go-to-market efforts for EVERSANA. His career spans more than 20 years in corporate strategy and business development, customer engagement, entrepreneurship and technology. Most recently in EVERSANA, he led the growth and expansion of the EVERSANA CONSULTING team across the North American and European regions. Prior to joining EVERSANA, he was a senior leader at various consulting firms and technology companies, helping contribute to the successful development and launch of products across therapeutic and medical device categories. He holds a bachelor’s degree in electrical engineering from Northwestern University and a Master of Business Administration from Harvard Business School.

Matt Wilkins
Senior Director, Provider Networks and Strategic Accounts
G1 Therapeutics

Krista Pinto
President, Deployment Solutions
Eversana

With more than 25 years of experience in the pharmaceutical industry, Krista leads EVERSANA’s Deployment Solutions service line. Propelled with power of data, analytics and digital technology, Krista is transforming the strategy, activation and impact of field-based commercial, medical and market access teams to drive stronger program performance for therapies worldwide. Recently recognized as a MM&M Hall of Femme Honoree and a two-time Rising Star by the Healthcare Businesswoman’s Association, Krista holds a Bachelor’s Degree from the University of Delaware.

Register Free: https://www.pharmexec.com/pe/idn-trends

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Gen Li
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Gaugarin Oliver
August 1st 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
Stock.adobe.com
August 1st 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity
August 1st 2025

Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity

Don Tracy, Associate Editor
The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 1st 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 1st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Gaugarin Oliver
August 1st 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Peter Ax, UpScriptHealth
August 1st 2025

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.
Stock.adobe.com
August 1st 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity
August 1st 2025

Superluminal Medicines Advances Selective MC4R Agonist Toward Clinical Trials for Obesity

Don Tracy, Associate Editor
The MC4R agonist targets rare genetic and hypothalamic obesity, with potential as a combination or maintenance therapy for general obesity alongside GLP-1 agents.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.